UK markets open in 3 hours 37 minutes

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.2100-0.1000 (-3.02%)
At close: 04:00PM EDT
3.3500 +0.14 (+4.36%)
After hours: 07:36PM EDT

Cellectar Biosciences, Inc.

100 Campus Drive
Florham Park, NJ 07932
United States
608 441 8120
https://www.cellectar.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 20

Key executives

NameTitlePayExercisedYear born
Mr. James V. CarusoPresident, CEO & Director846.48kN/A1959
Mr. Chad J. Kolean CPAVP, CFO & Secretary453.22kN/A1964
Mr. Jarrod LongcorChief Operating Officer625.32kN/A1973
Mr. Darrell Shane LeaChief Commercial OfficerN/AN/A1973
Dr. Andrei Shustov M.D.Senior Vice President of MedicalN/AN/A1971
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Corporate governance

Cellectar Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.